142 related articles for article (PubMed ID: 12113040)
1. Docetaxel improves survival and reduces risk of relapse in node-positive early-stage breast cancer.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):242-3. PubMed ID: 12113040
[No Abstract] [Full Text] [Related]
2. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
[TBL] [Abstract][Full Text] [Related]
3. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Crown J
Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Hudis C
Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Trudeau ME
Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
[TBL] [Abstract][Full Text] [Related]
7. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
9. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
12. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
13. The clinical rationale for developing docetaxel (Taxotere).
Armand JP
Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
[TBL] [Abstract][Full Text] [Related]
14. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
15. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
16. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
17. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
19. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
Klaassen U; Seeber S
Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
[No Abstract] [Full Text] [Related]
20. Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer.
Salminen E; Bergman M; Huhtala S; Jekunen A; Ekholm E
Anticancer Res; 2000; 20(5C):3663-8. PubMed ID: 11268436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
